Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The binding of [125I]iodine-labelled corticotropin releasing factor (CRF) was studied using peripheral blood lymphocytes from normal donors and Alzheimer's disease (AD) patients. The high affinity binding of [125I]CRF was found in the membranes of various immunocytes. Monocytes and T cells displayed binding which was several times greater than the binding of brain (cortical) cells. The immunocyte CRF binding was significantly (P less than 0.001) lower in 14 out of 18 (78%) AD patients relative to non-AD controls, suggesting the association of CRF in the pathology of AD. Our data demonstrate that blood immunocytes can be used to analyze deficiency of neurohormone sites in neuropsychiatric diseases, e.g., AD.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0165-2478(88)90061-2 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!